Philips secures FDA clearance for Verida spectral CT system
Philips has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Verida system. The device is…
17 Apr 2026
First patient receives JANX014 dose in Janux’s trial for mCRPC
Janux Therapeutics has announced the dosing of its first patient in a Phase I clinical trial evaluating JANX014 for metastatic castration-resistant prostate cancer (mCRPC). The multicentre, first-in-human, open-label trial will…
17 Apr 2026
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Daiichi Sankyo has signed a research partnership with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology. The agreement involves Daiichi Sankyo Research Institute Boston…
16 Apr 2026
Phantom Neuro secures approval for muscle-machine interface trial
Phantom Neuro has secured approval to initiate its first-in-human trial of the Phantom X system, a minimally invasive muscle-machine interface, in Australia, for prosthesis control. This development marks an essential…
16 Apr 2026
Precision receives CTA approval to expand ELIMINATE-B study
Precision BioSciences has received clinical trial application (CTA) approval to expand its global ELIMINATE-B study of PBGENE-HBV, an in vivo gene editing therapy for chronic hepatitis B. The regulatory clearance…
16 Apr 2026
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for patients with extensive-stage small cell lung cancer (ES-SCLC) and other…
15 Apr 2026
GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial
GlycoNex has received Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approval to commence a first-in-human Phase I clinical trial of GNX1021, its lead antibody-drug conjugate (ADC) candidate, for advanced gastrointestinal…